Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With Insulin Requiring Diabetes Mellitus on a Basal-bolus Regimen

NCT00604344 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00604344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00604344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With Insulin Requiring Diabetes Mellitus on a Basal-bolus Regimen
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2003
Completion date
March 31, 2005
Enrollment
401 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1